Tadalafil Tablet
Product Images NDC 68071-3753

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3753 3)

Label for Tadalafil 20 mg tablets by NuCare Pharmaceuticals, Inc., showing a 30-count unit. The label includes the NDC 68071-3753-3, manufacturer information as Zhejiang Huahai Pharmaceutical Co., China, and storage instructions at 68-77°F. It displays a warning to keep out of reach of children and indicates the product is prescription only.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, the active ingredient in the reviewed drug product. The structure depicts the molecular arrangement of tadalafil's chemical components.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A four-panel line graph figure showing changes in blood pressure over time. The panels depict differences between tadalafil and placebo in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure measured in mmHg across time points from 0 to 96 hours. Error bars indicate variability at each time point.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing changes in systolic blood pressure over time up to 24 hours post-dose. The top graph shows standing systolic blood pressure changes comparing tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows similar comparisons for supine systolic blood pressure. Both graphs plot blood pressure (mmHg) on the y-axis and time post-dose (hours) on the x-axis.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

Line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil with 8 mg doxazosin or placebo with 8 mg doxazosin at 08:00 and 20:00 dosing times. The x-axis is time after administration, and the y-axis shows systolic BP changes ranging from -20 to +20 mmHg.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph displaying plasma tadalafil concentration (µg/L) over time (hours) for three dosing scenarios: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph includes error bars showing variability at each time point, illustrating the pharmacokinetic profiles of tadalafil concentrations in plasma.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph depicting the change from baseline in IPSS total score over 12 weeks, comparing tadalafil tablets 5 mg with placebo. The graph shows greater improvement with tadalafil, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph depicting the change from baseline in IPSS Total Score over 12 weeks of treatment with tadalafil tablets 5 mg versus placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline. Tadalafil shows a greater decrease in score compared to placebo, with statistical significance indicated at week 4.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

Line graph depicting the least-squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride and Placebo/Finasteride treatment groups. The graph shows measurements at 0, 4, 12, and 26 weeks, with Tadalafil/Finasteride consistently demonstrating greater changes compared to placebo.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

Line graph showing change from baseline in IPSS total score over a 12-week treatment duration comparing tadalafil tablets 5 mg with placebo. The graph indicates greater score reduction with tadalafil, particularly noticeable after 4 weeks and sustained through 12 weeks, with a statistically significant difference at week 12 (p<0.01). The x-axis represents weeks of treatment, and the y-axis represents change in IPSS total score.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.